{"id":273,"date":"2020-11-30T07:00:00","date_gmt":"2020-11-30T15:00:00","guid":{"rendered":"https:\/\/caam.tech\/?p=273"},"modified":"2020-11-30T12:11:52","modified_gmt":"2020-11-30T20:11:52","slug":"caamtech-researchers-synthesize-and-structurally-characterize-deprocin-hydrochloride","status":"publish","type":"post","link":"https:\/\/caam.tech\/caamtech-researchers-synthesize-and-structurally-characterize-deprocin-hydrochloride\/","title":{"rendered":"CaaMTech Researchers Synthesize and Structurally Characterize Deprocin Hydrochloride"},"content":{"rendered":"\n
CaaMTech scientists have successfully synthesized and crystallographically characterized deprocin (4-HO-DPT) hydrochloride. The research was published under the title \u201cThe hydrochloride salt of 4-hydroxy-N,N-di-n-propyltryptamine (4-HO-DPT)<\/a>\u201d in IUCrData, a peer-reviewed publication from the International Union of Crystallography (IUCr). The research builds on CaaMTech\u2019s November 2019 publication of the first structural characterization of deprocin<\/a>.<\/p>\n\n\n\n Deprocin, also known as 4-HO-DPT, is a structural analog of psilocin, the active metabolite of psilocybin. Psilocybin is the most well-known psychedelic compound present in \u201cmagic mushrooms\u201d. Deprocin, not known to exist in nature, was first synthesized by Repke et al. in 1977. Alexander and Ann Shulgin reported the synthesis (and consumption) of 4-HO-DPT in the book TiHKAL<\/em>, though little scientific research (aside from CaaMTech\u2019s recent work) has been conducted with deprocin since.<\/p>\n\n\n\n Deprocin hydrochloride is one of several psilocin analogs synthesized by CaaMTech as a part of CaaMTech\u2019s collaboration with the Manke Lab at UMass Dartmouth. Access to multiple psilocin analogs offers CaaMTech researchers a numerical advantage over others when selecting the pharmacological profile most appropriate for the treatment of a given indication. Deprocin hydrochloride will proceed to the DDRU at NIDA IRP where further research will be conducted as a part of CaaMTech\u2019s preclinical drug development program.<\/p>\n\n\n\n